Semaglutide Cost in India: Pricing, Access & Stocking
A clinical reference on semaglutide cost in India: mechanism, real side-effect data, generic pricing after patent expiry, and hospital pharmacy stocking.
This covers the mechanism, the real gastrointestinal and thyroid-risk evidence, India's regulatory and pricing timeline, and why a hospital's ability to stock this molecule reliably now matters more than it did a year ago.
What is semaglutide and how does it work?
Semaglutide is a GLP-1 receptor agonist that stimulates the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying and increase satiety signalling in the brain. That combined effect drives both its glycaemic benefit in type 2 diabetes and its weight-loss effect in obesity, since delayed gastric emptying and central satiety signalling reduce intake independent of the insulin pathway.
The same mechanism explains most of its adverse-effect profile too, since slowed gastric emptying is directly responsible for the gastrointestinal symptoms that dominate real-world discontinuation data.
What is the real side-effect profile?
A systematic review and network meta-analysis of GLP-1 receptor agonists found nausea, vomiting, diarrhoea and constipation were the dominant adverse events across the class, with semaglutide specifically linked to higher vomiting and constipation risk than comparators. A separate review of randomised trials reported nausea in roughly 2–20% of patients and diarrhoea in 1.4–13% across ten trials, alongside nasopharyngitis, headache and elevated lipase as less common events.
Thyroid carcinogenicity has drawn the most regulatory attention of any single concern. A systematic literature review assessing thyroid carcinogenic risk found reported thyroid cancer incidence in semaglutide-treated patients under 1%, which the reviewed evidence characterised as not indicating a significant elevated risk, though it remains a monitored area given the drug's mechanism-based signal in rodent studies.
How is semaglutide regulated in India, and when did generics arrive?
CDSCO approved Ozempic, the type 2 diabetes indication, and separately approved Wegovy for the obesity indication, with Wegovy available in the Indian market since June 2025 as the only CDSCO-approved obesity-indication semaglutide product at that point. Novo Nordisk's core Indian patent on semaglutide expired on 21 March 2026, and multiple domestic manufacturers, including Dr Reddy's, Zydus, Alkem, Sun Pharma and Glenmark, launched generic versions on the day of expiry.
Semaglutide is not currently listed as a scheduled formulation under NPPA's Drug Price Control Order, which means it sits outside the fixed-ceiling-price mechanism that governs drugs like statins and does not carry an NPPA-set maximum price the way a scheduled molecule would.
What has patent expiry actually done to cost?
Innovator pricing before generic entry ran roughly ₹8,800–11,175 a month for Ozempic and up to ₹16,400 for Wegovy. After patent expiry, generics priced far lower: Natco's vial ran roughly ₹1,290–1,750 by dose, and Glenmark launched at a weekly cost near ₹325, the sharpest driver of falling semaglutide cost since launch.
Innovator brands responded with reported price cuts of roughly 36–48% in April 2026, narrowing but not closing the gap to generic pricing. A hospital pharmacy budgeting for this molecule should treat any of these figures as a snapshot from a fast-moving, non-scheduled market rather than a fixed reference price, and should verify current cost against its own distributor quote before ordering.
Why does hospital-level stocking of this molecule matter now?
Semaglutide moved in roughly a year from a high-cost specialty drug to genuine mass-market demand, and a hospital that hasn't revisited its formulary since before the March 2026 patent expiry is very likely under-stocked for current demand.
An unstocked prescription for a drug this newly affordable is also one a patient is now motivated to seek out actively rather than quietly skip, since the cost barrier that used to suppress fill rates has largely disappeared. Our guide on prescription leakage and hospital revenue loss covers how a stockout on a newly high-demand molecule compounds faster than on a stable, long-established one.
Does a managed pharmacy model help with a fast-moving molecule like this?
A managed or in-house hospital pharmacy model is built to track exactly this kind of demand shift, since reorder points and stocking depth need to move with real prescribing volume rather than a static annual formulary review. A molecule whose cost dropped more than 90% in weeks needs its stocking assumptions revisited on a similar timescale, not a yearly one.
Our managed hospital pharmacy services guide covers how a managed pharmacy model adjusts stocking to real demand data rather than a fixed catalogue, which is exactly what a molecule moving through a semaglutide cost shift this large needs. Our pharmacy inventory management guide covers the reorder discipline that prevents both understocking a suddenly popular drug and overstocking one whose price is still falling.
Sources
- 1Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials — National Institutes of Health, National Library of Medicine
- 2Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis — National Institutes of Health, National Library of Medicine
- 3Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy — National Institutes of Health, National Library of Medicine
- 4Central Drugs Standard Control Organisation — Drugs and Cosmetics Act 1940 and Rules 1945
- 5India's GLP-1 moment is here — the weight-loss drug wars begin — Forbes India, 2026
- 6India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top — CNBC, 23 March 2026
*Written by Dr. Anurag Sharma, MBBS, MS (Orthopaedics) — Consultant Orthopaedic Surgeon and Assistant Professor at S.M.S. Medical College and Hospital, Jaipur. Last updated 23 July 2026.*
*This article is a clinical reference for prescribers and hospital administrators. It is informational only, is not a substitute for professional medical advice, and does not recommend any dose or treatment for any individual patient. Pricing is a market snapshot as of the sources' publication dates and changes frequently in a non-scheduled market; verify current cost before purchase. Consult a qualified physician for patient-specific decisions.*
FAQ
Frequently asked questions
Novo Nordisk's core Indian patent on semaglutide expired on 21 March 2026, and multiple domestic manufacturers launched generic versions the same day, which introduced direct price competition against the innovator brands Ozempic and Wegovy.
No. Semaglutide is not currently listed as a scheduled formulation under NPPA's Drug Price Control Order, so it does not have a government-fixed ceiling price the way statins or several other essential medicines do.
Both contain semaglutide, but they carry different CDSCO approvals for different indications, Ozempic for type 2 diabetes and Wegovy specifically for obesity, and are not automatically interchangeable prescriptions.
Gastrointestinal symptoms, particularly nausea, vomiting, diarrhoea and constipation, are the most commonly reported adverse events across systematic review data, consistent with its gastric-emptying mechanism of action.
Systematic review data on semaglutide-treated patients found thyroid cancer incidence under 1%, characterised as not indicating a significantly elevated risk, though it remains an area of ongoing monitoring given the mechanism-based signal seen in animal studies.
Dr. Ananya DeshpandeMBBS, DM (Endocrinology)
Consultant Endocrinologist
Dr. Ananya Deshpande is a consultant endocrinologist writing on diabetes and insulin therapy, thyroid disorders, GLP-1 agonists, and metabolic conditions.